Technosphere inhaled insulin: Is faster better?

Diabetes Care

Volumn 38, Issue 12, 2015, Pages 2282-2284

  Leahy, Jack L ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA;

BLOOD FLOW; CYTOTOXICITY; DISEASE DURATION; DRUG ABSORPTION; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE PERSONNEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; NOTE; OUTCOME ASSESSMENT;

EID: 84962409108     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dci15-0002     Document Type: Note

References (23)

1. Santos Cavaiola T, Edelman S. Inhaled insulin: A breath of fresh air? A review of inhaled insulin. Clin Ther 2014;36:1275-1289.
2. Angelo R, Rousseau K, Grant M, Leone-Bay A, Richardson P. Technosphere insulin: defining the role of Technosphere particles at the cellular level. J Diabetes Sci Technol 2009;3: 545-554.
3. Cassidy JP, Amin N, Marino M, et al. Insulin lung deposition and clearance following Technosphere insulin inhalation powder administration. Pharm Res 2011;28:2157-2164.
4. Raskin P, Heller S, Honka M, et al. Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere insulin or usual antidiabetes treatment: A randomized trial. Diabetes Obes Metab 2012;14: 163-173.
5. Scheuch G, Kohlhaeufl MJ, Brand P, Siekmeier R. Clinical perspectives on pulmonary systemic and macromolecular delivery. Adv Drug Deliv Rev 2006;58:996-1008.
6. Siekmeier R, Hofmann T, Scheuch G, Pokorski M. Aerosolized GLP-1 for treatment of diabetes mellitus and irritable bowel syndrome. Adv Exp Med Biol 2015;849:23-38.
7. Boss AH, Petrucci R, Lorber D. Coverage of prandial insulin requirements by means of an ultra-rapid-acting inhaled insulin. J Diabetes Sci Technol 2012;6:773-779.
8. Luzi L, De Fronzo RA. Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. Am J Physiol 1989;257:E241-E246.
9. Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects. J Clin Invest 1967;46:1954-1962.
10. Mitrakou A, Kelley D, Mokan M, et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 1992;326:22-29.
11. Bruce DG, Chisholm DJ, Storlien LH, Kraegen EW. Physiological importance of deficiency in early prandial insulin secretion in noninsulin-dependent diabetes. Diabetes 1988;37: 736-744.
12. Bode BW, McGill JB, Lorber DL, Gross JL, Chang P-C, Bregman DB; Affinity 1 Study Group. Inhaled Technosphere insulin compared with injected prandial insulin in type 1 diabetes: A randomized 24-week trial. Diabetes Care 2015; 38:2266-2273.
13. Lee JJ, Dassau E, Zisser H, Harvey RA, Jovanovǐc L, Doyle FJ 3rd. In silico evaluation of an artificial pancreas combining exogenous ultrafast-acting Technosphere insulin with zone model predictive control. J Diabetes Sci Technol 2013;7:215-226.
14. Zisser H, Dassau E, Lee JJ, Harvey RA, Bevier W, Doyle FJ 3rd. Clinical results of an automated artificial pancreas using Technosphere inhaled insulin to mimic first-phase insulin secretion. J Diabetes Sci Technol 2015;9:564-572.
15. Rosenstock J, Franco D, Korpachev V, et al.; Affinity 2 Study Group. Inhaled Technosphere insulin versus inhaled Technosphere placebo in insulin-naïve subjects with type 2 diabetes inadequately controlled on oral antidiabetes agents. Diabetes Care 2015;38:2274-2281.
16. Rosenstock J, Bergenstal R, Defronzo RA, et al.; 0008 Study Group. Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulinnaive type 2 diabetes suboptimally controlled with oral agents. Diabetes Care 2008;31:2177-2182.
17. Holman RR, Thorne KI, Farmer AJ, et al.; 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-1730.
18. Bretzel RG, Nuber U, LandgrafW, Owens DR, Bradley C, Linn T. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): An open randomised controlled trial. Lancet 2008;371:1073-1084.
19. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial. Ann Intern Med 2005;143:559-569.
20. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: A randomized, controlled trial. Ann Intern Med 2011;154:103-112.
21. Bergenstal RM, Johnson M, Powers MA, et al. Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. Diabetes Care 2008;31:1305-1310.
22. Heinemann L, Muchmore DB. Ultrafast-acting insulins: state of the art. J Diabetes Sci Technol 2012;6:728-742.
23. Cahn A, Miccoli R, Dardano A, Del Prato S. New forms of insulin and insulin therapies for the treatment of type 2 diabetes. Lancet Diabetes Endocrinol 2015;3:638-652.